Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Association Between Childhood Obesity and Myopia: A Prospective Cohort Study

18 de noviembre de 2026 actualizado por: Weina Liu, Southeast University, China

This prospective observational cohort study will examine the association between obesity and myopia in children and adolescents. Approximately 600 participants aged 6 to 18 years will be enrolled at the Fourth Affiliated Hospital of Nanjing Medical University, including 300 participants with obesity and 300 participants with a body mass index within the normal range.

Participants will not be assigned to any study intervention. The study will collect information from body measurements, body composition assessments, eye examinations, lifestyle questionnaires, follow-up assessments, and existing clinical records. The investigators will evaluate whether obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat, are associated with myopia, axial length, refractive status, and changes in these outcomes over time. Lifestyle factors such as outdoor activity, near work, screen use, sleep, and diet will also be considered.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a single-center, prospective, observational cohort study involving children and adolescents aged 6 to 18 years who attend the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Approximately 600 participants will be enrolled, including 300 participants with obesity and 300 participants with a body mass index within the normal range. Obesity will be defined according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018).

No randomization, masking, or study-related clinical intervention will be performed. At baseline, the study will collect anthropometric measurements, body composition data, ophthalmic examination results, and lifestyle questionnaire data. Planned follow-up assessments will be used to evaluate changes in refractive status, axial length, scleral thickness, and myopia progression.

The principal study outcomes include myopia status and changes in axial length, spherical equivalent refraction, scleral thickness, and myopia progression. The study will examine associations between these outcomes and obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat.

Information on age, sex, parental history of myopia, birth history, medical history, medication use, outdoor activity, near work, screen use, sleep, and diet will be collected as potential confounding factors. Existing clinical laboratory results obtained during routine medical care, including blood lipids, fasting blood glucose, fasting insulin, C-peptide, and glycated hemoglobin, may be included in exploratory analyses when available.

The study will not collect additional blood, stool, or other biological samples solely for research purposes and will not increase the frequency or volume of blood collection. If residual blood remaining after routine clinical testing is available and its use is permitted by the ethics approval and informed consent, it may be used for related laboratory measurements without additional blood collection. The absence of existing laboratory results or residual blood will not affect study eligibility.

Statistical analyses will include group comparisons, multivariable linear or logistic regression, and linear mixed-effects models for repeated follow-up measurements. Analyses will adjust for relevant demographic, familial, and lifestyle factors.

Tipo de estudio

De observación

Inscripción (Estimado)

600

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Weina Liu, PHD
  • Número de teléfono: +86 18751951966
  • Correo electrónico: weinaliu@seu.edu.cn

Ubicaciones de estudio

    • Jiangsu
      • Nanjing, Jiangsu, Porcelana
        • Reclutamiento
        • The Fourth Affiliated Hospital of Nanjing Medical University
        • Contacto:
          • Weina Liu, PHD
          • Número de teléfono: +86 18751951966
          • Correo electrónico: weinaliu@seu.edu.cn

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 18 años (Niño, Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The study population will consist of approximately 600 children and adolescents aged 6 to 18 years attending the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Potential participants will be identified through the pediatric outpatient system and referrals from outpatient physicians. Approximately 300 participants will be enrolled in the obesity cohort and 300 in the normal-BMI cohort according to WS/T 586-2018. Enrollment requires written informed consent from a legal guardian and assent from the child or adolescent, as applicable.

Descripción

Inclusion Criteria:

  • Aged 6 to 18 years and able to cooperate with anthropometric measurements, ophthalmic examinations, questionnaire assessments, and follow-up visits.
  • For the obesity cohort, body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018); for the normal-BMI cohort, body mass index is within the normal range.
  • Best-corrected visual acuity of at least 0.8 in both eyes, with no apparent strabismus, opacity of the refractive media, or ocular structural abnormality.
  • The participant and legal guardian understand the study, voluntarily sign the applicable informed consent and assent documents, and are expected to comply with study procedures.
  • Able to complete the questionnaires and planned follow-up assessments.

Exclusion Criteria:

  • An ocular disease that may affect visual acuity or measurement of refractive status, including cataract, glaucoma, fundus disease, apparent strabismus, or another ocular structural abnormality.
  • A severe systemic disease or neurodevelopmental disorder that prevents cooperation with study examinations or follow-up.
  • A secondary condition or factor that substantially affects growth, development, or assessment of body weight.
  • Recent receipt of a myopia-control intervention that may substantially affect the evaluation of myopia progression when complete information about the intervention cannot be obtained.
  • Poor anticipated adherence, inability to complete follow-up, or withdrawal of informed consent by the legal guardian.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Obesity Cohort

Approximately 300 children and adolescents aged 6 to 18 years whose body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

The program should emphasize the health consequences of obesity and evidence-based weight management strategies, including maintaining a balanced diet, controlling energy intake, increasing physical activity, reducing sedentary behavior and screen time, and ensuring adequate sleep. Instruction, individualized counseling, and family involvement should be incorporated to improve health awareness and self-management skills and facilitate the development of a healthy lifestyle.

Normal-BMI Cohort

Approximately 300 children and adolescents aged 6 to 18 years whose body mass index is within the normal range according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Axial Length
Periodo de tiempo: Baseline and 24 months

Axial length will be measured in millimeters for each eye using the same non-contact optical biometer at baseline and follow-up. Change in axial length (ΔAL) will be calculated as the value at 24 months minus the baseline value. Positive values indicate axial elongation. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔAL will also be evaluated.

Baseline and 24 months
Change From Baseline in Spherical Equivalent Refractive Error
Periodo de tiempo: Baseline and 24 months

Spherical equivalent refractive error will be calculated for each eye as spherical power plus one-half of cylindrical power and expressed in diopters (D), based on cycloplegic autorefraction. Change in spherical equivalent refractive error (ΔSE) will be calculated as the value at 24 months minus the baseline value. A negative change indicates a myopic shift. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔSE will also be evaluated.

Baseline and 24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Scleral Thickness
Periodo de tiempo: Baseline and 24 months

Scleral thickness will be measured in micrometers at the same predefined anatomical location using optical coherence tomography at baseline and follow-up. Change in scleral thickness (ΔST) will be calculated as the value at 24 months minus the baseline value. A negative change indicates scleral thinning. Changes will be compared between children and adolescents with obesity and those with normal weight.

Baseline and 24 months
Change From Baseline in Regional Choroidal Thickness at 24 Months
Periodo de tiempo: Baseline and 24 months

Intraocular pressure, corneal curvature radius, mean keratometry, central corneal thickness, and anterior chamber depth will be measured in both eyes using the same standardized ophthalmic instruments at baseline and at the 24-month follow-up. Changes will be calculated as the 24-month value minus the corresponding baseline value. Intraocular pressure will be expressed in mmHg, corneal curvature radius and anterior chamber depth in millimeters, mean keratometry in diopters, and central corneal thickness in micrometers. Each parameter will be analyzed and reported separately.

Baseline and 24 months
Change From Baseline in Regional Retinal Thickness at 24 Months
Periodo de tiempo: Baseline and 24 months

Retinal thickness will be measured in micrometers at predefined temporal, central foveal, and nasal locations in both eyes using optical coherence tomography. Change at each location will be calculated as the value at 24 months minus the corresponding baseline value. Measurements from the temporal, central foveal, and nasal locations will be analyzed and reported separately.

Baseline and 24 months
Change From Baseline in Fasting Lipid Profile at 24 Months
Periodo de tiempo: Baseline and 24 months

Fasting lipid profile will include total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, all expressed in mmol/L. Laboratory results obtained during routine clinical care will be collected at baseline and at 24 months when available. Change in each lipid parameter will be calculated as the 24-month value minus the corresponding baseline value. Each lipid parameter will be analyzed and reported separately. No additional blood sampling will be performed solely for this study.

Baseline and 24 months
Body Fat Percentage
Periodo de tiempo: Baseline and 24 months

Body fat percentage will be estimated using bioelectrical impedance analysis and expressed as a percentage of total body mass.

Baseline and 24 months
Body Fat Mass
Periodo de tiempo: Baseline and 24 months

Fat mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

Baseline and 24 months
Body Muscle Mass
Periodo de tiempo: Baseline and 24 months

Muscle mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

Baseline and 24 months
Total Body Water
Periodo de tiempo: Baseline and 24 months

Total body water will be estimated using bioelectrical impedance analysis and expressed in liters (L).

Baseline and 24 months
Change From Baseline in Fasting Plasma Glucose at 24 Months
Periodo de tiempo: Baseline and 24 months

Change in fasting plasma glucose will be calculated as the 24-month value minus the baseline value and expressed in mmol/L.

Baseline and 24 months
Change From Baseline in Fasting Insulin at 24 Months
Periodo de tiempo: Baseline and 24 months

Change in fasting insulin will be calculated as the 24-month value minus the baseline value and expressed in µIU/mL.

Baseline and 24 months
Change From Baseline in C-Peptide at 24 Months
Periodo de tiempo: Baseline and 24 months

Change in C-peptide concentration will be calculated as the 24-month value minus the baseline value and expressed in pmol/L.

Baseline and 24 months
Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Months
Periodo de tiempo: Baseline and 24 months

Change in hemoglobin A1c (HbA1c) will be calculated by subtracting the baseline HbA1c percentage from the 24-month HbA1c percentage. The change will be expressed in percentage points.

Baseline and 24 months
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at 24 Months
Periodo de tiempo: Baseline and 24 months

At each visit, HOMA-IR will be calculated as fasting plasma glucose (mmol/L) multiplied by fasting insulin (µIU/mL), divided by 22.5, when both measurements are available from the same visit. Change will be calculated as the 24-month HOMA-IR value minus the baseline HOMA-IR value. HOMA-IR is a unitless index.

Baseline and 24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de julio de 2025

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

14 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SFY20250704-K185

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .